Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : U.S. infectious disease group backs Gilead's remdesivir for COVID-19 treatment

11/23/2020 | 11:02am EST

Nov 23 (Reuters) - The top U.S. infectious disease medical association said on Monday that Gilead Sciences Inc's antiviral drug remdesivir should be used for hospitalized COVID-19 patients despite a World Health Organization (WHO) recommendation last week against its use.

The Infectious Diseases Society of America (IDSA) in updated guidelines said its experts back the drug for use in severe COVID-19 patients based on a clinical trial showing it reduced hospital stays. The WHO study that led to its recommendation against the drug suggested it had no benefit in saving lives or reducing the need for mechanical breathing assistance.

"As hospitals around the United States fill up, the IDSA panel views the effect of remdesivir speeding up time to recovery to be an important benefit," Dr. Rajesh Gandhi, co-chair of the society's COVID-19 treatment and management guidelines expert panel, said on a call with reporters. "Better medicines that improve survival are clearly needed."

Unlike the trial that led to its U.S. regulatory approval, the WHO's study was not placebo-controlled. Studies with a placebo comparison are generally considered more scientifically rigorous than those without a control group.

The IDSA also has advised against the routine use of Eli Lilly and Co's COVID-19 antibody treatment bamlanivimab, which received U.S. emergency use authorization. The IDSA panel said it recommended against its routine use for ambulatory patients, but that it may still be appropriate for patients with increased risks after a discussion with their doctor.

"Antibodies may end up having a role. I think we just need more definitive data," Dr. Gandhi said. "I want to keep our eye on what benefit they may end up having as well as which patients are most likely to benefit."

It said Roche Holdings Ag's rheumatoid arthritis drug Actemra, known chemically as tocilizumab, is not recommended for routine use in hospitalized COVID-19 patients, saying there was still not enough evidence supporting its benefits. (Reporting by Rebecca Spalding Editing by Bill Berkrot)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 1.49% 63.33 Delayed Quote.8.70%
ROCHE HOLDING AG 1.47% 316.65 Delayed Quote.2.48%
All news about GILEAD SCIENCES, INC.
01/15STRIDES PHARMA SCIENCE : Arm Gets US FDA Nod for HIV/AIDS Treatment Drug
MT
01/13GILEAD SCIENCES : Statement on Recent Events in Washington, D.C.
PU
01/12INSIDER TRENDS : Bridge Bancorp Insider Receives Stock Award, Buy Trend Intact
MT
01/12GILEAD SCIENCES : Chris Freeman, Vice President of HIV Business Unit at Gilead S..
AQ
01/12GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares
AQ
01/12GILEAD SCIENCES : Working With Vir Biotechnology to Evaluate Therapeutic Combina..
MT
01/12GILEAD SCIENCES : and Vir Biotechnology Establish Clinical Collaboration to Expl..
AQ
01/11Gilead Lifts Guidance as Remdesivir Sales Surge; CEO Expects Treatment to Be ..
MT
01/11SECTOR UPDATE : Health Care Stocks Mixed Premarket Monday
MT
01/11GILEAD SCIENCES : Raises Product Sales Guidance on Remdesivir Demand, Narrows Ea..
DJ
More news
Financials (USD)
Sales 2020 24 225 M - -
Net income 2020 39,3 M - -
Net Debt 2020 24 871 M - -
P/E ratio 2020 9 112x
Yield 2020 4,27%
Capitalization 79 386 M 79 386 M -
EV / Sales 2020 4,30x
EV / Sales 2021 4,16x
Nbr of Employees 11 800
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 72,04 $
Last Close Price 63,33 $
Spread / Highest target 57,9%
Spread / Average Target 13,7%
Spread / Lowest Target -8,42%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458
GENMAB A/S9.09%28 585